Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
373
-
Total 13F shares, excl. options
-
96,602,103
-
Shares change
-
+7,902,110
-
Total reported value, excl. options
-
$6,617,629,592
-
Value change
-
+$540,380,977
-
Put/Call ratio
-
93%
-
Number of buys
-
215
-
Number of sells
-
166
-
Price
-
$68.49
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2024
As of 30 Jun 2024 Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) had 443 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 96,602,103 shares of stock of the company.
Largest 10 holders included FMR LLC, VANGUARD GROUP INC, BlackRock Inc., WASATCH ADVISORS LP, JPMORGAN CHASE & CO, Avoro Capital Advisors LLC, Invesco Ltd., Bellevue Group AG, NORGES BANK, and STATE STREET CORP.
This table shows 443 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.